Abdullah O Alenezi1, Elizabeth Tai2, Arash Jaberi2, Andrew Brown3, Sebastian Mafeld2, Graham Roche-Nagle4. 1. Joint Department of Medical Imaging, University Health Network - Toronto General Hospital, Toronto, ON, Canada. abdullahoalenezi@gmail.com. 2. Joint Department of Medical Imaging, University Health Network - Toronto General Hospital, Toronto, ON, Canada. 3. Niagara Health, St. Catherines, ON, Canada. 4. Department of Vascular Surgery, University Health Network - Toronto General Hospital, Toronto, ON, Canada.
Abstract
PURPOSE: To determine whether low total psoas muscle area (tPMA), as a surrogate for sarcopaenia, is a predictor of adverse outcomes in patients undergoing advanced EVAR. MATERIALS AND METHODS: A retrospective review of medical records was performed for 257 patients who underwent advanced EVAR (fenestrated or branched technique) in a single tertiary centre from 1 January 2008 to 1 September 2019. The study cohort was divided into tertiles based on tPMA measurement performed independently by two observers from a peri-procedural CT scan at the level of mid-L3 vertebral body. The low tertile was considered sarcopaenic. Logistic regression analysis was used to assess the association of tPMA with 30-day mortality and post-procedural complications. Univariable analysis and adjusted multivariable Cox regression were used to assess the association of tPMA with all-cause mortality. RESULTS: A total of 257 patients comprised 193 males and 64 females with the mean age of 75.4 years (± 6.8) were included. Adjusted multivariable Cox regression revealed an 8% reduction in all-cause mortality for every 1 cm2 increase in tPMA, P < 0.05. TPMA was associated with 30-day mortality (OR 0.85, 95% CI 0.75-0.96, P < 0.05) and spinal cord ischaemia (SCI) (OR 0.89, 95% CI 0.82-0.97, P < 0.05). For remaining post-procedural complications, tPMA was not a useful predictive tool. TPMA correlated negatively with hospital stay length (rs-0.26, P < 0.001). Patients with lower tPMA were more likely to be discharged to a rehabilitation center (OR 0.93, 95% CI 0.87-0.98 , P < 0.05). CONCLUSION: Measurement of tPMA can be a useful predictive tool for adverse outcomes after advanced EVAR. LEVEL OF EVIDENCE: Level 3, Retrospective cohort study.
PURPOSE: To determine whether low total psoas muscle area (tPMA), as a surrogate for sarcopaenia, is a predictor of adverse outcomes in patients undergoing advanced EVAR. MATERIALS AND METHODS: A retrospective review of medical records was performed for 257 patients who underwent advanced EVAR (fenestrated or branched technique) in a single tertiary centre from 1 January 2008 to 1 September 2019. The study cohort was divided into tertiles based on tPMA measurement performed independently by two observers from a peri-procedural CT scan at the level of mid-L3 vertebral body. The low tertile was considered sarcopaenic. Logistic regression analysis was used to assess the association of tPMA with 30-day mortality and post-procedural complications. Univariable analysis and adjusted multivariable Cox regression were used to assess the association of tPMA with all-cause mortality. RESULTS: A total of 257 patients comprised 193 males and 64 females with the mean age of 75.4 years (± 6.8) were included. Adjusted multivariable Cox regression revealed an 8% reduction in all-cause mortality for every 1 cm2 increase in tPMA, P < 0.05. TPMA was associated with 30-day mortality (OR 0.85, 95% CI 0.75-0.96, P < 0.05) and spinal cord ischaemia (SCI) (OR 0.89, 95% CI 0.82-0.97, P < 0.05). For remaining post-procedural complications, tPMA was not a useful predictive tool. TPMA correlated negatively with hospital stay length (rs-0.26, P < 0.001). Patients with lower tPMA were more likely to be discharged to a rehabilitation center (OR 0.93, 95% CI 0.87-0.98 , P < 0.05). CONCLUSION: Measurement of tPMA can be a useful predictive tool for adverse outcomes after advanced EVAR. LEVEL OF EVIDENCE: Level 3, Retrospective cohort study.
Authors: L M Drudi; K Phung; M Ades; J Zuckerman; L Mullie; O K Steinmetz; D I Obrand; J Afilalo Journal: Eur J Vasc Endovasc Surg Date: 2016-10-21 Impact factor: 7.069
Authors: Allyson L Hale; Kayla Twomey; Joseph A Ewing; Eugene M Langan; David L Cull; Bruce H Gray Journal: Vasc Med Date: 2016-02-05 Impact factor: 3.239
Authors: Ali F Aburahma; John E Campbell; Albeir Y Mousa; Stephen M Hass; Patrick A Stone; Akhilesh Jain; Aravinda Nanjundappa; L Scott Dean; Tammi Keiffer; Joseph Habib Journal: J Vasc Surg Date: 2011-02-16 Impact factor: 4.268
Authors: Roger A Fielding; Bruno Vellas; William J Evans; Shalender Bhasin; John E Morley; Anne B Newman; Gabor Abellan van Kan; Sandrine Andrieu; Juergen Bauer; Denis Breuille; Tommy Cederholm; Julie Chandler; Capucine De Meynard; Lorenzo Donini; Tamara Harris; Aimo Kannt; Florence Keime Guibert; Graziano Onder; Dimitris Papanicolaou; Yves Rolland; Daniel Rooks; Cornel Sieber; Elisabeth Souhami; Sjors Verlaan; Mauro Zamboni Journal: J Am Med Dir Assoc Date: 2011-03-04 Impact factor: 4.669
Authors: Rana Canavati; Alistair Millen; John Brennan; Robert K Fisher; Richard G McWilliams; Jagjeeth B Naik; Srinivasa R Vallabhaneni Journal: J Vasc Surg Date: 2012-10-06 Impact factor: 4.268
Authors: Reza Indrakusuma; Jendé L Zijlmans; Hamid Jalalzadeh; R Nils Planken; Ron Balm; Mark J W Koelemay Journal: Eur J Vasc Endovasc Surg Date: 2017-11-20 Impact factor: 7.069
Authors: Timothy C Huber; Nicole Keefe; James Patrie; Margaret C Tracci; Daniel Sheeran; John F Angle; Luke R Wilkins Journal: J Vasc Interv Radiol Date: 2019-10-30 Impact factor: 3.464
Authors: Brian A Derstine; Sven A Holcombe; Brian E Ross; Nicholas C Wang; Grace L Su; Stewart C Wang Journal: Sci Rep Date: 2018-07-27 Impact factor: 4.379
Authors: Caterina Beatrice Monti; Paolo Righini; Maria Chiara Bonanno; Davide Capra; Daniela Mazzaccaro; Matteo Giannetta; Gabriele Maria Nicolino; Giovanni Nano; Francesco Sardanelli; Massimiliano M Marrocco-Trischitta; Francesco Secchi Journal: J Clin Med Date: 2022-07-12 Impact factor: 4.964